SCHEMBL3517864

SCHEMBL3517864

O=C(O)c1c(O)c(-c2cccc(F)c2)cc2ncc(Br)nc12

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GPR35 Q9HC97 2/20 0.42
KMO O15229 2/20 0.40
DHODH Q02127 3/20 0.40
CHEK2 O96017 2/20 0.38
PIK3R1 P27986 1/20 0.38
PIK3CA P42336 1/20 0.38
PLK4 O00444 1/20 0.38
AURKA O14965 1/20 0.38
DAPK3 O43293 1/20 0.38
CDK1 P06493 1/20 0.38
PIM1 P11309 1/20 0.38
CDK2 P24941 1/20 0.38
FLT4 P35916 1/20 0.38
KDR P35968 1/20 0.38
MAPK9 P45984 1/20 0.38
CSNK1D P48730 1/20 0.38
GSK3A P49840 1/20 0.38
GSK3B P49841 1/20 0.38
PLK1 P53350 1/20 0.38
CSNK2A1 P68400 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3520006 0.79 EGLN3 (0.43) DHODHCSNK1DTOP2AEGLN3KDM4E
SCHEMBL3521733 0.75 TOP1 (0.42) KMODHODHCHEK2PLK4AURKA
SCHEMBL3520359 0.74 EGLN3 (0.44) DHODHPIK3CAKDRMAPK9BCHE
SCHEMBL3522299 0.74 EGLN3 (0.60) KMOBCHEACHEEGLN3ATR
SCHEMBL3522019 0.74 TOP2A (0.38) KMODHODHCHEK2PLK4AURKA
SCHEMBL3526186 0.74 KMO (0.40) KMODHODHCHEK2PLK4AURKA
SCHEMBL3519778 0.72 EGLN3 (0.57) EGLN3KDM4EATREGLN1
SCHEMBL3761128 0.70 EGLN3 (0.55) BCHEACHEEGLN3ATREGLN1
SCHEMBL3524401 0.69 EGLN3 (0.46) GPR35KMODHODHTOP2AEGLN3
SCHEMBL3520731 0.69 SMN1; SMN2 (0.41) DHODHKDRBCHEKDM4EHPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100305133-A1 Prolyl Hydroxylase Inhibitors SMITHKLINE BEECHAM CORPORATION 2010-12-02 US disclosed
EP-2227770-A2 PROLYL HYDROXYLASE INHIBITORS GlaxoSmithKline LLC (US) 2010-09-15 EP disclosed
WO-2009073497-A2 PROLYL HYDROXYLASE INHIBITORS SMITHKLINE BEECHAM CORPORATION (US) 2009-06-11 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100305133-A1 Prolyl Hydroxylase Inhibitors HIF1AN, EGLN3, EGLN2 GPR35 2548/4885KMO 350/4885DHODH 20/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.